The goal of this clinical core is to provide high numbers of samples of PBMC from subjects with acute / early phase HCV infection, allowing large-scale studies of immunologic parameters for investigators throughout the collaborative center. Funding of this core would allow continued identification of acute / early stage HCV infection in the Massachusetts State Prison system. Rationale includes the high number of young injection drug users entering the prison systems yearly, who are therefore at risk for HCV infection. The identification of acute HCV had traditionally been reliant on symptoms or laboratory abnormalities rather than exposure history, but our prior funding period established a system based on history-based risk factors to screen for early-stage HCV infection. This brief 1-2 minute questionnaire was designed to assist providers in identifying persons at risk for recent acquisition of HCV by injection drug use. The successful implementation in the MA state prison system identified a large number () of persons with acute HCV over a short period of time. In addition, longitudinal sample acquisition was greatly enhanced by this project. This represents the first systematic study of acute HCV among persons entering the prison system, providing critical information regarding the overall prevalence, clinical characteristics, and treatment outcomes of acute HCV in incarcerated individuals. Funding from this clinical core would allow continuation of this unique and valuable resource for both members of this Collaborative Center as well as allow collaboration with other groups examining questions not being addressed directly by this grant.
This core is complementary to the Brazilian cohort, insofar that it provides samples from injection drug users, whose immunologic parameters may differ in key aspects from those with other modes of acquisition of HCV. The high quality of the samples and ability to obtain longitudinal samples is also relevant and critical to the success of the other projects contained within this application.
|Rodrigo, Chaturaka; Eltahla, Auda A; Bull, Rowena A et al. (2016) Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 214:1383-1389|
|Hajarizadeh, B; Grady, B; Page, K et al. (2015) Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat 22:708-17|
|Doyle, J S; Deterding, K; Grebely, J et al. (2015) Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 22:1020-32|
|Onofrey, Shauna; Aneja, Jasneet; Haney, Gillian A et al. (2015) Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med 163:254-61|
|Sacks-Davis, Rachel; Grebely, Jason; Dore, Gregory J et al. (2015) Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis 212:1407-19|
|Baumert, Thomas F; Fauvelle, Catherine; Chen, Diana Y et al. (2014) A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol 61:S34-44|
|Zignego, A L; Wojcik, G L; Cacoub, P et al. (2014) Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 15:500-5|
|Kroy, Daniela C; Ciuffreda, Donatella; Cooperrider, Jennifer H et al. (2014) Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146:550-61|
|Cosgrove, Cormac; Berger, Christoph T; Kroy, Daniela C et al. (2014) Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver. PLoS One 9:e105950|
|Grebely, Jason; Page, Kimberly; Sacks-Davis, Rachel et al. (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109-20|
Showing the most recent 10 out of 47 publications